|
|
|
| Effect of Gemcitabine combined with Erlotinib in the treatment of advanced pancreatic cancer |
| WANG Min ZHAO Jian-hua |
Department of Oncology,the First People′s Hospital in Jingdezhen City,Jiangxi Province,Jingdezhen 333000,China |
|
|
|
|
Abstract Objective To investigate the effect of Gemcitabine combined with Erlotinib in the treatment of advanced pancreatic cancer.Methods Forty patients with advanced pancreatic cancer admitted to our hospital from January 2017 to January 2018 were selected as the research objects for retrospective analysis.They were divided into control group(20 cases) and observation group (20 cases) according to different treatment methods.Patients in the observation group were treated with Gemcitabine combined with Erlotinib,while patients in the control group were treated with Gemcitabine combined with Tegafur.The clinical therapeutic effects,clinical benefits (pain relief intensity ≥50%,analgesic drug dosage reduction ≥50%,weight gain >7%) and adverse reactions (leukopenia,thrombocytopenia,rash,nausea and vomiting,transaminase elevation) were compared between the two groups.Results The total effective rate of patients in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).The total clinical benefit rate of patients in the observation group was higher than that in the control group,and the difference was statistically significant (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion After Gemcitabine combined with Erlotinib is adopted for advanced pancreatic cancer patients,the total treatment efficiency and clinical total benefit rate of the patients are improved,the incidence rate of adverse reactions of the patients is not increased,and the method has higher clinical application value.
|
|
|
|
|
|
| [1] |
邱纯，陈俊民，孙达统，等.吉西他滨联合厄洛替尼对晚期胰腺癌患者预后及基质金属蛋白酶2的影响[J].河北医药，2017，39（17）：2650-2652.
|
| [2] |
谢斌，韦文萍，刘勇，等.高能聚焦超声刀联合单药吉西他滨化疗治疗局部晚期胰腺癌的临床观察[J].安徽医药，2019，23（4）：792-794.
|
| [3] |
乔翠霞，张新峰，程旭锋，等.吉西他滨加替吉奥联合沙利度胺治疗老年晚期胰腺癌的临床观察[J].中国老年学杂志，2019，39（5）：1061-1063.
|
| [4] |
牛广宇.立体定向放疗联合盐酸吉西他滨对局部晚期胰腺癌患者止痛效果及预后的影响[J].医学理论与实践，2019，32（5）：689-690.
|
| [5] |
霍利伟，张力.胰腺癌吉西他滨及顺铂化疗联合放射性粒子植入治疗疗效研究[J].世界最新医学信息文摘，2019，19（20）：166，169.
|
| [6] |
张树彬，吕海涛，段佳悦，等.替吉奥并吉西他滨治疗晚期胰腺癌的临床效果[J].精准医学杂志，2019，34（1）：42-44.
|
| [7] |
魏蕾，李自雄，秦叔逵，等.吉西他滨单药或联合白蛋白结合型紫杉醇治疗东亚人群晚期胰腺癌临床疗效的荟萃分析[J].临床肿瘤学杂志，2019，24（2）：137-144.
|
| [8] |
沈俊，周锐，王建祥.吉西他滨联合厄洛替尼对晚期胰腺癌的临床疗效研究[J].中国临床药理学杂志，2016，32（7）：615-617.
|
| [9] |
方昀，来梦茹，葛宇清，等.胰腺癌药物治疗的现状与展望[J].中国中药杂志，2019，44（8）：1509-1516.
|
| [10] |
李慧.分析护理干预对结直肠癌术后肠造口患者自我管理能力及生活质量的影响[J].智慧健康，2019，5（1）：122-123.
|
| [11] |
郭君兰，胡彦伟，王丽华.替吉奥与吉西他滨治疗老年晚期胰腺癌的疗效比较[J].中国医院用药评价与分析，2018，18（12）：1647-1648.
|
| [12] |
沈睿智，陈暑波，王琦.白蛋白结合型紫杉醇联合替吉奥治疗吉西他滨治疗失败进展期胰腺癌的临床价值分析[J].名医，2018（11）：221.
|
| [13] |
杨骏宇，陈文显，张鸣杰.超声引导下胰腺占位穿刺在胰腺癌诊断中的应用[J].中国现代医生，2019，57（12）：92-95.
|
| [14] |
陈娟，陈锦云.胰腺癌的化学治疗及生物靶向治疗相关研究进展[J].医学综述，2014，20（13）：2347-2349.
|
| [15] |
戴永美，刘振华，陈峥，等.厄洛替尼联合含吉西他滨化疗方案治疗转移性胰腺癌的临床观察[J].药品评价，2012，9（30）：14-15，18.
|
|
|
|
